Repurposing and re-optimising drugs that disrupt glycoprotein folding to treat COVID-19
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA143639
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$989,895.77Funder
National Health and Medical Research Council (NHMRC)Research Location
AustraliaLead Research Institution
Walter and Eliza Hall Institute of Medical ResearchResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
As of June 2020, COVID-19 has infected over 7.3 million people and killed over 413,000 in the six months since it emerged. It has pushed many healthcare systems and economies to breaking point. We recently discovered that a known drug is effective at stopping the virus under laboratory conditions. This research will determine exactly how the drug works, evaluate it's potential in pre-clinical models, and re-optimise the drug's antiviral properties to ensure that we can prevent future pandemics.